In addition, the combination of SGLT2 inhibitors with insulin therapy has been suggested to yield favorable outcomes in terms of glycemic control while potentially minimizing the adverse effects traditionally associated with insulin, such as hypoglycemia, which can complicate the clinical picture in patients with T2DM [56,57]. Here, SLC5A2 is linked to Hypoglycemia.